Pharmacokinetics of famotidine in patients with cystic fibrosis

Journal of Clinical Pharmacology

Volumn 38, Issue 11, 1998, Pages 1010-1016

  Maish, William A ^a,b   McCubbin, Michael M ^c,e   Letzig, Lynda G ^f,g   Farrar III, Henry C ^f,g   Kearns, Gregory L ^c,d,e  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^e CHILDREN S MERCY HOSPITAL   (United States)

^f UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^g ARKANSAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAMOTIDINE;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; COMPARTMENT MODEL; CYSTIC FIBROSIS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CLEARANCE; MALE; ORAL DRUG ADMINISTRATION;

EID: 0031757935     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127009803801104     Document Type: Article

References (44)

1. Zentler-Munro PL, Fitzpatrick WJF, Batten JC, Northfield TC: Effect of intrajejunal acidity on aqueous phase bile acid and lipid concentration in pancreatic steatorrhea due to cystic fibrosis. Gut 1984;25:500-507.
2. Cox KL, Isenberg JN, Osher AB, Dooley RR: The effect of cimetidine on maldigestion in cystic fibrosis. J Pediatr 1979;94:488-492.
3. Carroccio A, Pardo F, Montalto G, Iapichino L, Soresi M, Averna MR, et al: Use of famotidine in severe exocrine pancreatic insufficiency with persistent maldigestion on enzymatic replacement therapy: a long-term study in cystic fibrosis. Dig Dis Sci 1992;37:1441-1446.
4. Shepherd RW, Cooksley WGE, Cooke WDD: Improved growth and clinical nutritional and respiratory changes in response to nutritional therapy in cystic fibrosis. J Pediatr 1980;97:351-357.
5. Cucchiara S, Raia V, Minella R, Frezza T, De Vizia B, De Ritis G: Ultrasound measurement of gastric emptying time in patients with cystic fibrosis and effect of ranitidine on delayed gastric emptying. J Pediatr 1996;128:485-488.
6. Bacigalupo A, van Lint MT, Marmont AM: Cimetidine-induced coma. Lancet 1979;1:45-46.
7. Russell WL, Lopez LM: Cimetidine-induced mental status changes: case report and literature review. Am J Hosp Pharm 1980;37:1667-1671.
8. Thompson J, Lilly J: Cimetidine-induced cerebral toxicity in children (letter). Lancet 1979;1:725.
9. Feldman M, Burton ME: Histamine2-receptor antagonists: standard therapy for acid-peptic diseases (second of two parts). N Engl J Med 1990;323:1749-1755.
10. Dimand RJ: Use of H2-receptor antagonists in children. DICP Ann Pharmacother 1990;24(Suppl):S42-S46.
11. Bramhall D, Levine M: Possible interaction of ranitidine with phenytoin. Drug Intell Clin Pharm 1988;22:979-980.
12. Skinner MH, Lenert L, Blaschke TF: Theophylline toxicity subsequent to ranitidine administration: a possible drug-drug interaction. Am J Med 1989;86:129-132.
13. Bachmann KA, Sullivan TJ, Jauregui L, Reese J, Miller K, Levine L: Drug interactions of H2-receptor antagonists. Scand J Gastroenterol Suppl 1994;206:14-19.
14. Kearns GL, Reed MD: Clinical pharmacokinetics in infants and children: a reappraisal. Clin Pharmacokinet 1989;17(Suppl 1):29-67.
15. Davis PB, Drumm M, Konstan MW: Cystic fibrosis. Am J Respir Crit Care Med 1996;154:1229-1256.
16. Kearns GL: Hepatic drug metabolism in cystic fibrosis: recent developments and future directions. Ann Pharmacother 1993;27:74-79.
17. MacDonald NE, Anas NG, Peterson RG, Schwartz RH, Brooks JG, Powell KR: Renal clearance of gentamicin in cystic fibrosis. J Pediatr 1983;103:985-990.
18. Leeder JS, Spino M, Isles AF, Tesoro AM, Gold R, MacLeod SM: Ceftazidime disposition in acute and stable cystic fibrosis. Clin Pharmacol Ther 1984;36:355-362.
19. Levy J, Smith AL, Koup JR, Williams-Warren J, Ramsey B: Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study. J Pediatr 1984;105:117-124.
20. Spino M, Chai RP, Isles AF, Thiessen JJ, Tesoro A, Gold R, et al: Cloxacillin absorption and disposition in cystic fibrosis. J Pediatr 1984;105:829-835.
21. Vogelstein B, Kowarski AA, Lietman PS: The pharmacokinetics of amikacin in children. J Pediatr 1977;91:333-339.
22. Kearns GL, Mallory GB, Crom WR, Evans WE: Enhanced hepatic drug clearance in patients with cystic fibrosis. J Pediatr 1990;117:972-979.
23. Kraus G, Krishna DR, Chmelarsch D, Schmid M, Klotz U: Famotidine: pharmacokinetic properties and suppression of acid secretion in paediatric patients following cardiac surgery. Clin Pharmacokinet 1990;18:77-81.
24. Jahr JS, Burckart G, Smith SS, Shapiro J, Cook DR: Effects of famotidine on gastric pH and residual volume in pediatric surgery. Acta Anaesthesiol Scand 1991;35:457-460.
25. James LP, Marshall JD, Heulitt MH, Wells TG, Letzig L, Kearns GL: Pharmacokinetics and pharmacodynamics of famotidine in children. J Clin Pharmacol 1996;36:48-54.
26. James LP, Kearns GL: Pharmacokinetics and pharmacodynamics of famotidine in paediatric patients. Clin Pharmacokinet 1996;31:103-110.
27. Nagita A, Manago M, Aoki S, Mino M, Suzuki K, Ashida K: Pharmacokinetics and pharmacodynamics of famotidine in children with gastroduodenal ulcers. Ther Drug Monit 1994;16:444-449.
28. Treem WR, Davis P, Hyams JS: Suppression of gastric acid secretion by intravenous administration of famotidine in children. J Pediatr 1991;118:812-816.
29. Ryan JR, Vargas R, McMahon FG, Chremos AN: Comparison of effects of oral and intravenous famotidine on inhibition of nocturnal gastric acid secretion. Am J Med 1986;81(Suppl 4B):60-64.
30. Echizen H, Shoda R, Umeda N, Ishizaki T: Plasma famotidine concentration versus intragastric pH in patients with upper gastrointestinal bleeding and in healthy subjects. Clin Pharmacol Ther 1988;44:690-698.
31. Taussig LM, Kattwinkel J, Friedewald WT, di Sant'Agnese PA: A new prognostic score and clinical evaluation system for cystic fibrosis. J Pediatr 1973;82:380-390.
32. Kroemer H, Klotz U: Pharmacokinetics of famotidine in man. Int J Clin Pharmacol Ther Toxicol 1987;25:458-463.
33. Gomeni R, Gomeni C: AUTOMOD: a polyalgorithm for integrated analysis of linear pharmacokinetic models. Comput Biol Med 1979;9:38-48.
34. Marquardt DW: An algorithm for least-squares estimation of nonlinear parameters. J Soc Indust Appl Math 1963;11:431-441.
35. Yamaoka K, Nakagawa T, Uno T: Application of Akaike's information criterion in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165-175.
36. Wagner JG: Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data. J Pharmacokinet Biopharm 1976;4:443-467.
37. Shargel L, Yu ABC: Applied Biopharmaceutics and Pharmacokinetics. East Norwalk, CT: Appleton-Century-Crofts, 1980.
38. Takabatake T, Ohta H, Mackawa M, Yamamoto Y, Ishida Y, Hara H, et al: Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function. Eur J Clin Pharmacol 1985;28:327-331.
39. Echizen H, Ishizaki T: Clinical pharmacokinetics of famotidine. Clin Pharmacokinet 1991;21:178-194.
40. Yeh KC, Chremos AN, Lin JH, Constanzer ML, Kanovsky SM, Hucker HB, et al: Single-dose pharmacokinetics and bioavailability of famotidine in man: results of multicenter collaborative studies. Biopharm Drug Dispos 1987;8:549-560.
41. Spino M, Chai RP, Isles AF, Balfe JW, Brown RG, Thiessen JJ, et al: Assessment of glomerular filtration rate and effective renal plasma flow in cystic fibrosis. J Pediatr 1985;107:64-70.
42. Ziemniak JA, Assael BM, Padoan R, Schentag JJ: The bioavailability and pharmacokinetics of cimetidine and its metabolites in juvenile cystic fibrosis patients: age related differences as compared to adults. Eur J Clin Pharmacol 1984;26:183-189.
43. Somogyi A, Rohner HG, Gugler R: Pharmacokinetics and bioavailability of cimetidine in gastric and duodenal ulcer patients. Clin Pharmacokinet 1980;5:84-94.
44. Miyake S, Yamada M, Iwamoto H, Yamashita S, Sugio Y: Effect of a new H2-blocker, famotidine, in reflux esophagitis among severely handicapped children. Clin Ther 1987;9:548-558.